LACK OF EFFECT OF 3 PUTATIVE VASOACTIVE-INTESTINAL-PEPTIDE RECEPTOR ANTAGONISTS ON VASOACTIVE INTESTINAL PEPTIDE-INDUCED SECRETORY RESPONSES IN RAT COLON

被引:15
作者
BURLEIGH, DE
KIRKHAM, SE
机构
[1] Department of Pharmacology, Queen Mary and Westfield College, London, E1 4NS, Mile End Road
关键词
VIP (VASOACTIVE INTESTINAL PEPTIDE) RECEPTOR ANTAGONIST; SHORT-CIRCUIT CURRENT; MUCOSA; COLON;
D O I
10.1016/0014-2999(93)90439-O
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have assessed the potential usefulness of three vasoactive intestinal peptide antagonists for investigating whether vasoactive intestinal peptide has a functional role as a secretomotor neurotransmitter at the neuroepithelial junction in rat colonic mucosa. Vasoactive intestinal peptide (VIP) increases short-circuit current in muscle-stripped preparations of rat colon. The response is unaffected by tetrodotoxin and can only be obtained when the peptide is applied to the basolateral side of the membrane. Three putative antagonists were tested for their ability to inhibit short-circuit current responses to vasoactive intestinal peptide. Vasoactive intestinal peptide-(10-28) (1 mu M and 3 mu M), human growth hormone releasing factor (human GRF) analogue [Ac-Tyr(1)]human GRF-(1-40)OH (0.1 mu M and 1 mu M) and [Lys(1),Pro(2,5),Arg(3,4),Tyr(6)]VIP (0.5 mu M) produced concentration-dependent increases in basal short-circuit current but were ineffective as antagonists to vasoactive intestinal peptide.
引用
收藏
页码:239 / 242
页数:4
相关论文
共 12 条
[1]  
BURLEIGH D E, 1990, British Journal of Pharmacology, V100, p480P
[2]   EVIDENCE AGAINST SUBSTANCE-P AS A NEUROTRANSMITTER AT THE NEUROEPITHELIAL JUNCTION IN RAT COLONIC MUCOSA [J].
BURLEIGH, DE ;
YULL, DN .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1992, 44 (03) :257-258
[4]   VASOACTIVE INTESTINAL POLYPEPTIDE-INDUCED CHLORIDE SECRETION BY A COLONIC EPITHELIAL-CELL LINE - DIRECT PARTICIPATION OF A BASOLATERALLY LOCALIZED NA+,K+,CL- COTRANSPORT SYSTEM [J].
DHARMSATHAPHORN, K ;
MANDEL, KG ;
MASUI, H ;
MCROBERTS, JA .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 75 (02) :462-471
[5]  
GOZES I, 1991, J PHARMACOL EXP THER, V257, P959
[6]  
KEAST JR, 1987, REV PHYSL BIOCH PHAR, V109, P2
[7]  
ODORISIO MS, 1987, FASEB J, V46, P192
[8]   VASOACTIVE-INTESTINAL-PEPTIDE RECEPTOR ANTAGONIST [4CL-D-PHE6, LEU17]VIP [J].
PANDOL, SJ ;
DHARMSATHAPHORN, K ;
SCHOEFFIELD, MS ;
VALE, W ;
RIVIER, J .
AMERICAN JOURNAL OF PHYSIOLOGY, 1986, 250 (04) :G553-G557
[9]  
RACUSEN LC, 1977, GASTROENTEROLOGY, V73, P790
[10]  
ROBBERECHT P, 1990, ARCH INT PHARMACOD T, V303, P51